4-amino-1-tert-butyl-3-(1'-naphthoxymethyl)pyrazolo<3,4-d>pyrimidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-amino-1-tert-butyl-3-(1'-naphthoxymethyl)pyrazolo<3,4-d>pyrimidine
• 英文别名: 4-amino-1-tert-butyl-3-(1'-naphthoxymethyl)pyrazolo[3,4-d]pyrimidine；1-Tert-butyl-3-(naphthalen-1-yloxymethyl)pyrazolo[3,4-d]pyrimidin-4-amine
• 化学式: C₂₀H₂₁N₅O
• 分子量: 347.42
• InChiKey: AMUSCCJWXVNQEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(萘-1-基氧基)乙酰氯 在 sodium hydride 、 碳酸氢钠 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 为溶剂， 反应 14.5h， 生成 4-amino-1-tert-butyl-3-(1'-naphthoxymethyl)pyrazolo<3,4-d>pyrimidine
  参考文献：
  名称：

  Generation of Monospecific Nanomolar Tyrosine Kinase Inhibitors via a Chemical Genetic Approach

  摘要：

  Selective protein kinase inhibitors are highly sought after as tools for studying cellular signal transduction cascades, yet few have been discovered due to the highly conserved fold of kinase catalytic domains. Through a combination of small molecule synthesis and protein mutagenesis, a highly potent (IC50 = 1.5 nM) and uniquely specific inhibitor (4-amino-1-tert-butyl-3-(1'-naphthyl)pyrazolo[3,4-d]pyrimidine) of a rationally engineered v-Src tyrosine kinase (Ile338Gly v-Src) has been identified. Both the potency and specificity of this compound surpass those of any known Src family tyrosine kinase inhibitors. The molecule strongly inhibits the engineered v-Src in whole cells but does not inhibit tyrosine phosphorylation in cells that express only wild-type tyrosine kinases. In addition, the inhibitor selectively disrupts transformation in cells that express the target v-Src. The structural degeneracy of kinase active sites should allow the same complementary inhibitor/protein design strategy to be widely applicable across this entire enzyme superfamily.

  DOI：

  10.1021/ja983267v

文献信息

• MODULATION OF PROTEIN TRAFFICKING
  申请人：Bulawa Christine Ellen

  公开号：US20100331297A1

  公开（公告）日：2010-12-30

  Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically acceptable salts or derivatives thereof.

  本发明提供用于治疗或改善由蛋白质运输缺陷所特征的一个或多个疾病的化合物和组合物。一种治疗由蛋白质运输受损所特征的疾病的方法包括向受试者施用或与细胞接触化合物I的药物或其药学上可接受的盐或衍生物。[公式在此]
• High affinity inhibitors for target validation and uses thereof
  申请人：Princeton University

  公开号：EP1321467A2

  公开（公告）日：2003-06-25

  An inhibitor that does not inhibit a catalytic activity of a wild-type protein kinase but inhibits the same catalytic activity of the corresponding mutant protein kinase, wherein the wild-type protein kinase and the mutant protein kinase are functionally similar.

  一种抑制剂，它不能抑制野生型蛋白激酶的催化活性，但能抑制相应突变型蛋白激酶的相同催化活性，其中野生型蛋白激酶和突变型蛋白激酶在功能上相似。
• HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF
  申请人：Princeton University

  公开号：EP1140938B1

  公开（公告）日：2003-08-27
• ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES
  申请人：Shokat Kevan M.

  公开号：US20090124638A1

  公开（公告）日：2009-05-14

  The present invention provides anti-inflammatory compounds useful in the treatment of diseases and conditions in which inflammation is involved in disease progression or the manifestation of symptoms of the disease or condition.
• Anti-Inflammatory Pyrazolopyrimndines
  申请人：Shokat Kevan M.

  公开号：US20110144134A1

  公开（公告）日：2011-06-16

  The present invention provides anti-inflammatory compounds useful in the treatment of diseases and conditions in which inflammation is involved in disease progression or the manifestation of symptoms of the disease or condition.